Rapid onset of action with alfuzosin 10mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial

This randomized, double- blind, placebo- controlled study was conducted to investigate whether alfuzosin 10mg once daily improves the maximum flow rate ( Q(max)) and lower urinary tract symptoms ( LUTS) of benign prostatic hyperplasia ( BPH) after 1 week and 1 month of treatment. A total of 372 men aged >= 50 years with symptomatic BPH received alfuzosin or placebo for 28 days. Qmax increased significantly from baseline at day 8 with alfuzosin ( P < 0.001 versus placebo); this improvement was evident within 24 h after the first dose and was maintained at day 29. LUTS improved from baseline with alfuzosin at day 8 ( P = 0.07 versus placebo) and day 29 ( P = 0.003 versus placebo). Alfuzosin 10mg once daily exhibits a rapid onset of action, with improvements in Qmax and LUTS maintained through 1 month of treatment.